- Home
- ACIC vs MLYS Comparison
ACIC vs MLYS Comparison
Compare ACIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- MLYS
- Stock Information
- Founded
- ACIC 1999
- MLYS 2019
- Country
- ACIC United States
- MLYS United States
- Employees
- ACIC N/A
- MLYS N/A
- Industry
- ACIC Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- MLYS Health Care
- Exchange
- ACIC Nasdaq
- MLYS Nasdaq
- Market Cap
- ACIC 556.0M
- MLYS 890.6M
- IPO Year
- ACIC N/A
- MLYS 2023
- Fundamental
- Price
- ACIC $10.90
- MLYS $37.42
- Analyst Decision
- ACIC Buy
- MLYS Strong Buy
- Analyst Count
- ACIC 1
- MLYS 6
- Target Price
- ACIC $16.00
- MLYS $42.60
- AVG Volume (30 Days)
- ACIC 172.0K
- MLYS 2.6M
- Earning Date
- ACIC 11-05-2025
- MLYS 11-10-2025
- Dividend Yield
- ACIC 4.60%
- MLYS N/A
- EPS Growth
- ACIC 14.01
- MLYS N/A
- EPS
- ACIC 1.63
- MLYS N/A
- Revenue
- ACIC $320,072,000.00
- MLYS N/A
- Revenue This Year
- ACIC $4.91
- MLYS N/A
- Revenue Next Year
- ACIC $4.16
- MLYS N/A
- P/E Ratio
- ACIC $6.66
- MLYS N/A
- Revenue Growth
- ACIC 33.90
- MLYS N/A
- 52 Week Low
- ACIC $8.82
- MLYS $8.24
- 52 Week High
- ACIC $15.08
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- ACIC 49.26
- MLYS 83.46
- Support Level
- ACIC $10.31
- MLYS $34.59
- Resistance Level
- ACIC $11.17
- MLYS $39.20
- Average True Range (ATR)
- ACIC 0.35
- MLYS 2.76
- MACD
- ACIC -0.03
- MLYS 1.02
- Stochastic Oscillator
- ACIC 34.75
- MLYS 92.66
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.